Cullen Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$75.6M Buy
2,693,507
+596,176
+28% +$15.9M 0.78% 43
2025
Q4
$52.2M Sell
2,097,331
-161,356
-7% -$4.07M 0.57% 51
2025
Q3
$57.6M Sell
2,258,687
-1,384,891
-38% -$34.2M 0.63% 49
2025
Q2
$88.3M Sell
3,643,578
-1,079,744
-23% -$25.2M 1.01% 35
2025
Q1
$120M Sell
4,723,322
-51,058
-1% -$1.34M 1.38% 35
2024
Q4
$127M Buy
4,774,380
+545,406
+13% +$14.8M 1.48% 32
2024
Q3
$122M Buy
4,228,974
+372,130
+10% +$10.9M 1.33% 37
2024
Q2
$108M Sell
3,856,844
-641,387
-14% -$17.7M 1.24% 38
2024
Q1
$125M Buy
4,498,231
+1,919,887
+74% +$53.3M 1.39% 36
2023
Q4
$74.2M Sell
2,578,344
-1,402,358
-35% -$42.4M 1.1% 35
2023
Q3
$132M Sell
3,980,702
-88,866
-2% -$3.14M 1.54% 32
2023
Q2
$149M Buy
4,069,568
+2,988
+0.1% +$116K 1.33% 32
2023
Q1
$166M Buy
4,066,580
+1,019,440
+33% +$44M 1.52% 26
2022
Q4
$156M Sell
3,047,140
-937,743
-24% -$45M 2% 18
2022
Q3
$174M Buy
3,984,883
+310,028
+8% +$15.1M 1.87% 22
2022
Q2
$193M Sell
3,674,855
-35,514
-1% -$1.81M 1.94% 15
2022
Q1
$192M Buy
3,710,369
+48,971
+1% +$2.54M 1.77% 24
2021
Q4
$216M Sell
3,661,398
-1,117,992
-23% -$55.4M 2.03% 17
2021
Q3
$206M Sell
4,779,390
-171,544
-3% -$7.6M 2.02% 16
2021
Q2
$194M Buy
4,950,934
+356,787
+8% +$13.9M 1.87% 19
2021
Q1
$166M Buy
4,594,147
+3,446,388
+300% +$122M 1.8% 20
2020
Q4
$42.2M Sell
1,147,759
-82,359
-7% -$3.02M 2.35% 15
2020
Q3
$42.8M Sell
1,230,118
-290,117
-19% -$10.2M 2.48% 13
2020
Q2
$47.2M Sell
1,520,235
-296,142
-16% -$10.1M 2.65% 13
2020
Q1
$56.2M Sell
1,816,377
-74,766
-4% -$2.55M 3.24% 6
2019
Q4
$70.3M Buy
1,891,143
+124,999
+7% +$4.45M 2.76% 9
2019
Q3
$60.2M Buy
1,766,144
+44,316
+3% +$1.61M 2.42% 16
2019
Q2
$70.8M Buy
1,721,828
+4,506
+0.3% +$179K 2.76% 10
2019
Q1
$69.2M Buy
1,717,322
+6,197
+0.4% +$248K 2.73% 9
2018
Q4
$70.9M Sell
1,711,125
-135,999
-7% -$5.65M 3.06% 7
2018
Q3
$77.2M Buy
1,847,124
+7,077
+0.4% +$272K 2.85% 2
2018
Q2
$63.3M Sell
1,840,047
-163,549
-8% -$5.59M 2.4% 16
2018
Q1
$67.5M Buy
2,003,596
+39,304
+2% +$1.35M 2.39% 17
2017
Q4
$67.5M Sell
1,964,292
-21,154
-1% -$721K 2.32% 20
2017
Q3
$67.2M Buy
1,985,446
+87,947
+5% +$2.83M 2.34% 21
2017
Q2
$60.5M Sell
1,897,499
-137,332
-7% -$4.33M 2.13% 26
2017
Q1
$66M Sell
2,034,831
-506,721
-20% -$16M 2.32% 21
2016
Q4
$78.3M Buy
2,541,552
+4,637
+0.2% +$142K 2.7% 15
2016
Q3
$81.5M Buy
2,536,915
+92,183
+4% +$3.08M 2.76% 15
2016
Q2
$81.7M Sell
2,444,732
-13,913
-0.6% -$444K 2.88% 14
2016
Q1
$69.1M Sell
2,458,645
-38,618
-2% -$1.1M 2.45% 20
2015
Q4
$76.5M Sell
2,497,263
-136,367
-5% -$4.29M 2.58% 18
2015
Q3
$78.5M Sell
2,633,630
-124,688
-5% -$4M 2.75% 15
2015
Q2
$87.7M Buy
2,758,318
+18,550
+0.7% +$605K 2.8% 15
2015
Q1
$90.4M Buy
2,739,768
+92,036
+3% +$2.93M 2.54% 19
2014
Q4
$78.3M Buy
2,647,732
+196,096
+8% +$5.62M 2.13% 27
2014
Q3
$68.8M Buy
2,451,636
+15,283
+0.6% +$429K 1.89% 26
2014
Q2
$68.6M Buy
+2,436,353
New +$69.4M 1.78% 27

Other funds holding PFE

Cullen Capital Management's PFE Position: Q1 2026 in Review

Cullen Capital Management increased its Pfizer (PFE) stake by 28% in Q1 2026, buying an estimated $15.9M and bringing the position to 2,693,507 shares worth $75.6M. The position accounts for 0.78% of the portfolio, ranked #43.

Cullen Capital Management first reported a position in PFE in Q2 2014 and has held it in 48 quarters since. The position peaked at $216M in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Cullen Capital Management held 2,693,507 shares of Pfizer worth $75.6M as of Q1 2026.
  • Cullen Capital Management bought 596,176 Pfizer shares in Q1 2026, an estimated $15.9M.
  • Pfizer made up 0.78% of Cullen Capital Management's portfolio in Q1 2026, its #43 holding.
  • Cullen Capital Management first reported a position in Pfizer in Q2 2014 and has held it in 48 quarters since.
  • Cullen Capital Management's Pfizer position peaked at $216M in Q4 2021.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Cullen Capital Management's 13F filing for Q1 2026, filed 15 May 2026.